t(11;14)(q13;q32)

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(11;14)(q13;q32)

Identity

Note t(11;14) is mainly found in mantle cell lymphoma, but also in B-prolymphocytic leukaemia, in plasma cell leukaemia, in splenic lymphoma with villous lymphocytes, in chronic lymphocytic leukaemia, and in multiple myeloma, herein briefly described; all these diseases involve a B-lineage lymphocyte.

t(11;14)(q13;q32) G- banding (left) - Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap Cytogenetics at theWaisman Center and R- banding (right) - Editor

Clinics and Pathology

Disease mantle cell lymphoma

Phenotype / cell stem origin B-cell non Hodgkin lymphoma of the low to intermediate grade

Epidemiology annual incidence 5/10⁶; median age: 65 yrs

Clinics advanced disease

Prognosis median survival: 3 to 4 yrs

Disease B-prolymphocytic leukaemia

Phenotype / cell stem origin chronic lymphoproliferative disorder affecting mature B-cells

Epidemiology rare disease; median age 70 yrs

Clinics patients often present with advanced stage disease

Prognosis median survival: 3 yrs

Disease plasma cell leukaemia

Phenotype / cell stem origin proliferation involving plasma cells

Epidemiology rare disorder

Prognosis median survival is less than a yr

Disease splenic lymphoma with villous lymphocytes

Phenotype / cell stem origin chronic B-cell lymphoproliferation

Epidemiology rare disorder; median age: 70 yrs

Clinics relatively benign clinical course

Prognosis 80% 5-yr survival

Disease chronic lymphocytic leukaemia

Phenotype / cell stem origin chronic B-cell lymphoproliferation

Epidemiology annual incidence 30/10⁶; median age: 60-80 yrs

Clinics often a slow evolutive disease

Prognosis highly variable according to the staging: from staging A: survival not reduced compared to age matched population, to staging C: median survival of 2 yrs

Disease multiple myeloma

Phenotype / cell stem origin malignant plasma cell proliferation (terminally differenciated B-cell)

Epidemiology annual incidence: 30/10⁶; median age: 60 yrs

Prognosis median survival: 3 yrs.

Cytogenetics

Cytogenetics Morphological t(11;14) has earlier been thought to be the hallmark of the mantle cell lymphoma; actually, the frequency of t(11;14) is: 50-70% in mantle cell lymphoma, 10-20% in B-prolymphocytic leukaemia, in plasma cell leukaemia, and in splenic lymphoma with villous lymphocytes, and 2-5% in chronic lymphocytic leukaemia, and in multiple myeloma.

Cytogenetics Molecular in particular interphase cytogenetics, are relevant in these diseases with an usually low mitotic index

Additional anomalies sole anomaly in only 10% of cases; part of a complex karyotype in 2/3 of cases; numerous recurrent anomalies found conjointly (which is the primary?), particularly: +3, +7, del(9p), +18, + mar, found in about 10% of cases each; other: del(1p), del(6q), del(7q), -8, +12, del(13q), del(17p)

Variants three way complex t(11;14; Var) exist and showed that the crucial event lies on der(14)

Genes involved and Proteins

Gene Name BCL1

Location 11q13

Dna / Rna 5 exons

Protein encodes the cyclin D1; role in the cell cycle control: G1 progression and G1/S transition

Gene Name IgH

Location 14q32

Result of the chromosomal anomaly

Hybrid gene
Description 5' BCL1 translocated on chromosome 14 near JH (junctions genes of IgH) and C in 3'; the breakpoint in BCL1 is in MTC (major translocation cluster), centromeric to the gene (in 5'), in 80% of cases, or dispersed in mTC1, 2, or 3 in 5'of the gene or in the 3' untranslated region of exon 5.

Fusion Protein
Description no fusion protein, but promoter exchange; the immunoglobulin gene enhancer stimulates the expression of BCL1

Oncogenesis overexpression of BCL1 accelerates passage through the G1 phase.

External links

Other database t(11;14)(q13;q32) Mitelman database (CGAP - NCBI)

Other database t(11;14)(q13;q32) CancerChromosomes (NCBI)

Other database	t(11;14)(q13;q32)	Mitelman database (CGAP - NCBI)
Other database	t(11;14)(q13;q32)	CancerChromosomes (NCBI)

Bibliography

Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias.

Rimokh R, Berger F, Delsol G, Charrin C, Berthˆ©as MF, Ffrench M, Garoscio M, Felman P, Coiffier B, Bryon PA

Blood. 1993 ; 81 (11) : 3063-3067.

PMID 8499640

Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32).

Kobayashi H, Kitano K, Saito H, Aoki K, Narita A, Terada N, Sonoyama M, Uchimaru K, Machii T, Motokura T

Cancer genetics and cytogenetics. 1995 ; 84 (1) : 69-72.

PMID 7497446

The ultrastructure of mantle cell lymphoma and other B-cell disorders with translocation t(11;14)(q13;q32).

Resnitzky P, Matutes E, Hedges M, Morilla R, Brito-Babapulle V, Khokhar T, Catovsky D

British journal of haematology. 1996 ; 94 (2) : 352-361.

PMID 8759896

Genes and chromosomes in chronic B-cell leukemia.

Crossen PE

Cancer genetics and cytogenetics. 1997 ; 94 (1) : 44-51.

PMID 9078290

Cytogenetics of lymphomas: a brief review of its theoretical and practical significance.

Donner LR

Cancer genetics and cytogenetics. 1997 ; 94 (1) : 20-26.

PMID 9078287

Cytogenetics and molecular genetics in multiple myeloma.

Feinman R, Sawyer J, Hardin J, Tricot G

Hematology/oncology clinics of North America. 1997 ; 11 (1) : 1-25.

PMID 9081201

Prognostic factors in chronic lymphocytic leukemia.

Hallek M, Kuhn-Hallek I, Emmerich B

Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997 ; 11 Suppl 2 : S4-13.

PMID 9178831

Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems.

Meusers P, Hense J, Brittinger G

Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997 ; 11 Suppl 2 : S60-S64.

PMID 9178843

Overexpression of PRAD1/cyclin D1 in plasma cell leukemia with t(11;14)(q13;q32).

Shimazaki C, Goto H, Araki S, Tatsumi T, Takahashi R, Hirai H, Kikuta T, Yamagata N, Ashihara E, Inaba T, Fujita N, Suzuki R, Nakagawa M

International journal of hematology. 1997 ; 66 (1) : 111-115.

PMID 9220667

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

Bosch F, Lˆ„pez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, Vallespˆ‚ T, Woessner S, Montserrat E

Cancer. 1998 ; 82 (3) : 567-575.

PMID 9452276

Contributor(s)

Written 05-1998 Jean-Loup Huret

Citation

This paper should be referenced as such :
Huret JL . t(11;14)(q13;q32). Atlas Genet Cytogenet Oncol Haematol. May 1998 .
URL : http://AtlasGeneticsOncology.org/Genes/t1114ID2021.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Sep 24 21:07:19 2008

Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

For comments and suggestions or contributions, please contact us

j.l.huret@chu-poitiers.fr.

Note	t(11;14) is mainly found in mantle cell lymphoma, but also in B-prolymphocytic leukaemia, in plasma cell leukaemia, in splenic lymphoma with villous lymphocytes, in chronic lymphocytic leukaemia, and in multiple myeloma, herein briefly described; all these diseases involve a B-lineage lymphocyte.


	t(11;14)(q13;q32) G- banding (left) - Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap Cytogenetics at theWaisman Center and R- banding (right) - Editor

Disease	mantle cell lymphoma
Phenotype / cell stem origin	B-cell non Hodgkin lymphoma of the low to intermediate grade
Epidemiology	annual incidence 5/10⁶; median age: 65 yrs
Clinics	advanced disease
Prognosis	median survival: 3 to 4 yrs

Disease	B-prolymphocytic leukaemia
Phenotype / cell stem origin	chronic lymphoproliferative disorder affecting mature B-cells
Epidemiology	rare disease; median age 70 yrs
Clinics	patients often present with advanced stage disease
Prognosis	median survival: 3 yrs

Disease	plasma cell leukaemia
Phenotype / cell stem origin	proliferation involving plasma cells
Epidemiology	rare disorder
Prognosis	median survival is less than a yr

Disease	splenic lymphoma with villous lymphocytes
Phenotype / cell stem origin	chronic B-cell lymphoproliferation
Epidemiology	rare disorder; median age: 70 yrs
Clinics	relatively benign clinical course
Prognosis	80% 5-yr survival

Disease	chronic lymphocytic leukaemia
Phenotype / cell stem origin	chronic B-cell lymphoproliferation
Epidemiology	annual incidence 30/10⁶; median age: 60-80 yrs
Clinics	often a slow evolutive disease
Prognosis	highly variable according to the staging: from staging A: survival not reduced compared to age matched population, to staging C: median survival of 2 yrs

Disease	multiple myeloma
Phenotype / cell stem origin	malignant plasma cell proliferation (terminally differenciated B-cell)
Epidemiology	annual incidence: 30/10⁶; median age: 60 yrs
Prognosis	median survival: 3 yrs.

Cytogenetics Morphological	t(11;14) has earlier been thought to be the hallmark of the mantle cell lymphoma; actually, the frequency of t(11;14) is: 50-70% in mantle cell lymphoma, 10-20% in B-prolymphocytic leukaemia, in plasma cell leukaemia, and in splenic lymphoma with villous lymphocytes, and 2-5% in chronic lymphocytic leukaemia, and in multiple myeloma.
Cytogenetics Molecular	in particular interphase cytogenetics, are relevant in these diseases with an usually low mitotic index
Additional anomalies	sole anomaly in only 10% of cases; part of a complex karyotype in 2/3 of cases; numerous recurrent anomalies found conjointly (which is the primary?), particularly: +3, +7, del(9p), +18, + mar, found in about 10% of cases each; other: del(1p), del(6q), del(7q), -8, +12, del(13q), del(17p)
Variants	three way complex t(11;14; Var) exist and showed that the crucial event lies on der(14)

Gene Name	BCL1
Location	11q13
Dna / Rna	5 exons
Protein	encodes the cyclin D1; role in the cell cycle control: G1 progression and G1/S transition

Description	5' BCL1 translocated on chromosome 14 near JH (junctions genes of IgH) and C in 3'; the breakpoint in BCL1 is in MTC (major translocation cluster), centromeric to the gene (in 5'), in 80% of cases, or dispersed in mTC1, 2, or 3 in 5'of the gene or in the 3' untranslated region of exon 5.

Description	no fusion protein, but promoter exchange; the immunoglobulin gene enhancer stimulates the expression of BCL1
Oncogenesis	overexpression of BCL1 accelerates passage through the G1 phase.